Latest Insider Transactions at Karyopharm Therapeutics Inc. (KPTI)
This section provides a real-time view of insider transactions for Karyopharm Therapeutics Inc. (KPTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karyopharm Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karyopharm Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 25
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+16.97%
|
-
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,887
-5.89%
|
$40,418
$14.83 P/Share
|
|
Feb 18
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,186
-2.24%
|
$16,604
$14.83 P/Share
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,675
+16.49%
|
-
|
|
Feb 15
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,850
+8.39%
|
-
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,858
-35.07%
|
$42,870
$15.52 P/Share
|
|
Feb 11
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,046
-4.94%
|
$30,690
$15.52 P/Share
|
|
Feb 11
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,748
-3.5%
|
$26,220
$15.52 P/Share
|
|
Feb 11
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
SELL
Open market or private sale
|
Direct |
2,046
-33.06%
|
$30,690
$15.52 P/Share
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,150
+50.0%
|
-
|
|
Feb 05
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+12.01%
|
-
|
|
Feb 05
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+47.72%
|
-
|
|
Feb 05
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+10.18%
|
-
|
|
Dec 18
2020
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$90,000
$18.0 P/Share
|
|
Dec 18
2020
|
Mansoor Raza Mirza |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$25,000
$5.43 P/Share
|
|
Dec 07
2020
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
20,000
-52.08%
|
$320,000
$16.07 P/Share
|
|
Dec 07
2020
|
Mansoor Raza Mirza |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$100,000
$5.43 P/Share
|
|
Dec 01
2020
|
Christopher Brett Primiano EVP, CBO, GC & Secretary |
SELL
Open market or private sale
|
Direct |
137,061
-93.7%
|
$2,330,037
$17.51 P/Share
|
|
Dec 01
2020
|
Christopher Brett Primiano EVP, CBO, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
137,061
+48.37%
|
$1,370,610
$10.42 P/Share
|
|
Nov 02
2020
|
Christopher Brett Primiano EVP, CBO, GC & Secretary |
SELL
Open market or private sale
|
Direct |
772
-14.58%
|
$10,808
$14.92 P/Share
|
|
Oct 30
2020
|
Tanya Lewis EVP, Chief Reg. Affairs |
SELL
Open market or private sale
|
Direct |
226
-29.54%
|
$3,390
$15.58 P/Share
|
|
Oct 28
2020
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
765
+50.0%
|
-
|
|
Oct 13
2020
|
Christopher Brett Primiano EVP, CBO, GC & Secretary |
SELL
Open market or private sale
|
Direct |
39,271
-51.33%
|
$667,607
$17.03 P/Share
|
|
Oct 13
2020
|
Christopher Brett Primiano EVP, CBO, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
39,271
+29.5%
|
$353,439
$9.8 P/Share
|
|
Oct 12
2020
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,500
-0.98%
|
$105,000
$14.89 P/Share
|
|
Oct 12
2020
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+0.49%
|
$0
$0.03 P/Share
|
|
Oct 12
2020
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
7,500
-0.98%
|
$105,000
$14.89 P/Share
|
|
Oct 12
2020
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
7,500
+0.49%
|
$0
$0.03 P/Share
|
|
Jul 15
2020
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
589
-1.34%
|
$11,191
$19.46 P/Share
|
|
Jul 11
2020
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,413
+5.29%
|
-
|